South & Central America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Admi

South & Central America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

The South & Central America infectious disease therapeutics market was valued at US$ 6,252.96 million in 2022 and is expected to reach US$ 8,167.05 million by 2030; it is estimated to register a CAGR of 3.4% from 2022 to 2030.

Growing Opportunities in Developing Nations Fuels South & Central America Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in Brazil are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

South & Central America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in South & Central America is sub segmented into Brazil, Argentina, and the Rest of South & Central America. The infectious disease therapeutics market in South & Central America is expected to grow due to increased prevalence of infectious diseases, surge in research activities, and rising healthcare expenditure by the regional countries. Brazil has made huge progress in the healthcare sector owing to expanding healthcare expenditure. According to the International Trade Administration, Brazil spends ~9.1% of its GDP on healthcare and is the major healthcare market in Latin America. The infectious disease therapeutics market in Brazil is estimated to boom owing to the increasing prevalence of infectious diseases.

Infectious diseases are still significant causes of death in Brazil. A survey revealed that a high burden of infectious disease was observed among men and children under 5 years of age, mainly due to HIV/AIDS. According to the data provided by the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, around 990,000 people were living with HIV and AIDS in Brazil. Thus, owing to the abovementioned factors, the infectious disease therapeutics market in Brazil is anticipated to grow during the forecast period.

South & Central America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Infectious Disease Therapeutics Market Segmentation

The South & Central America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the South & Central America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the South & Central America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the South & Central America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the South & Central America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the South & Central America infectious disease therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the South & Central America infectious disease therapeutics market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America infectious disease therapeutics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America infectious disease therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution. Show more